Healthcare provider profile · identity verified

Christopher L Yarter, MD

Family Practice · CENTRALIA, WA · NPI 1508859356

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	507	127
Levothyroxine Sodium	Levothyroxine Sodium	303	67
Losartan Potassium	Losartan Potassium	284	83
Amlodipine Besylate	Amlodipine Besylate	282	78
Lisinopril	Lisinopril	251	68
Omeprazole	Omeprazole	225	59
Tamsulosin Hcl	Tamsulosin Hcl	216	65
Rosuvastatin Calcium	Rosuvastatin Calcium	208	61
Metformin Hcl Er	Metformin Hcl	178	40
Metoprolol Succinate	Metoprolol Succinate	153	43
Trazodone Hcl	Trazodone Hcl	145	37
Metformin Hcl	Metformin Hcl	136	38
Tramadol Hcl	Tramadol Hcl	131	26
Pantoprazole Sodium	Pantoprazole Sodium	118	33
Escitalopram Oxalate	Escitalopram Oxalate	113	27
Albuterol Sulfate Hfa	Albuterol Sulfate	108	32
Gabapentin	Gabapentin	106	34
Eliquis	Apixaban	101	14
Hydrochlorothiazide	Hydrochlorothiazide	94	31
Fluticasone Propionate	Fluticasone Propionate	77	23
Simvastatin	Simvastatin	76	21
Alendronate Sodium	Alendronate Sodium	73	19
Potassium Chloride	Potassium Chloride	71	25
Pravastatin Sodium	Pravastatin Sodium	69	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	67	23
Allopurinol	Allopurinol	65	21
Sertraline Hcl	Sertraline Hcl	58	16
Zolpidem Tartrate	Zolpidem Tartrate	58	11
Lorazepam	Lorazepam	56	19
Clonazepam	Clonazepam	55	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	55	15
Duloxetine Hcl	Duloxetine Hcl	49	14
Citalopram Hbr	Citalopram Hydrobromide	47	15
Meloxicam	Meloxicam	46	13
Celecoxib	Celecoxib	45	12
Famotidine	Famotidine	44	12
Januvia	Sitagliptin Phosphate	43	11
Acyclovir	Acyclovir	42	suppressed
Furosemide	Furosemide	42	17
Lovastatin	Lovastatin	42	12
Lamotrigine	Lamotrigine	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	13
Carvedilol	Carvedilol	39	11
Valacyclovir	Valacyclovir Hcl	38	suppressed
Ezetimibe	Ezetimibe	36	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	suppressed
Baclofen	Baclofen	34	suppressed
Arnuity Ellipta	Fluticasone Furoate	33	suppressed
Atenolol	Atenolol	32	suppressed
Propranolol Hcl Er	Propranolol Hcl	32	suppressed
Spironolactone	Spironolactone	32	suppressed
Alprazolam	Alprazolam	31	12
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Finasteride	Finasteride	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Ozempic	Semaglutide	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Irbesartan	Irbesartan	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Primidone	Primidone	24	suppressed
Testosterone	Testosterone	24	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Prazosin Hcl	Prazosin Hcl	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Topiramate	Topiramate	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Prednisone	Prednisone	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Cholestyramine Light	Cholestyramine	15	suppressed
Colchicine	Colchicine	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Pentoxifylline	Pentoxifylline	14	suppressed
Ramipril	Ramipril	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	13	suppressed
Gemtesa	Vibegron	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Cephalexin	Cephalexin	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Azithromycin	Azithromycin	11	11
Hydrocortisone	Hydrocortisone	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error